Reported 4 months ago
Ro CEO Zach Reitano discusses the challenges of supply constraints on GLP-1 medications in the US, highlighting Ro's efforts to provide transparent supply information to patients in need. Reitano emphasizes Ro's mission of personalized healthcare and the company's proactive approach to address the shortage. He points out the unique situation in the US where a vast majority of the population is eligible for a specific drug, leading to severe supply-demand dynamics. Ro aims to crowdsource supply information through a tracker to streamline drug access for patients and healthcare providers.
Source: YAHOO